We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
108 hedge funds and large institutions have $56.4M invested in Lineage Cell Therapeutics in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
13% more funds holding
Funds holding: 96 → 108 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.79% less ownership
Funds ownership: 43.08% → 42.29% (-0.79%)
11% less capital invested
Capital invested by funds: $63.2M → $56.4M (-$6.78M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Holders
108
Holders Change
+12
Holders Change %
+12.5%
% of All Funds
2.13%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
21
Increased
27
Reduced
19
Closed
9
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$10K
Top Buyers
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$152K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$133K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$109K |
| 4 |
Morgan Stanley
New York
|
+$99.4K |
| 5 |
JP Morgan Chase
New York
|
+$88.6K |
